Debrisoquin (Debrisoquine)

An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.

Also Known As:

Networked: 166 relevant articles (3 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Branch, Robert A: 2 articles (02/2011 - 09/2006)
2.	Balahonova, N P: 1 article (12/2020)
3.	Garanina, I A: 1 article (12/2020)
4.	Kerchev, V V: 1 article (12/2020)
5.	Losik, E A: 1 article (12/2020)
6.	Skhirtladze, M R: 1 article (12/2020)
7.	Yakushina, I I: 1 article (12/2020)
8.	Chen, Xing-Long: 1 article (08/2016)
9.	Chen, Yi-Heng: 1 article (08/2016)
10.	Gao, Wei-Yang: 1 article (08/2016)

Related Diseases

1.	Hypertension (High Blood Pressure) 02/01/1976 - "The conclusion was that both drugs were equally effective in the doses studied and well tolerated and that debrisoquine is of value in the treatment of moderate hypertension." 01/01/1977 - "[Treatment of hypertension with the preparation Tendor]." 11/20/1973 - "[Therapeutic results with the hypotensive agent Declinax (debrisoquin) in mild and medium forms of hypertension]." 11/01/1972 - "Tolerance and side effects during long term treatment of hypertension with debrisoquine." 01/01/1970 - "Clinical observations on the use of debrisoquine sulphate (Declinas) in the treatment of hypertension."
2.	Lung Neoplasms (Lung Cancer) 08/01/1990 - "Overall, individuals who were extensive metabolizers of debrisoquine were at significantly greater risk of lung cancer than those who were poor or intermediate metabolizers (odds ratio = 6.1; 95% confidence interval = 2.2-17.1). " 01/01/1995 - "We examined the hypothesis that the genetically determined ability to metabolize debrisoquine identifies individuals at increased risk for lung cancer in a study designed to address some of the methodological criticisms of previous studies. " 07/01/1991 - "These data suggest that debrisoquine can be administered safely in a controlled clinical setting and will be useful for the characterization of lung cancer patients in biochemical epidemiology studies." 05/01/1997 - "Previous reports of the association between the debrisoquine polymorphism and lung cancer risk are conflicting. " 01/01/1995 - "While the concept that polymorphisms of metabolism may account for differential susceptibility to lung cancer is sound, debrisoquine metabolic phenotype was not associated with lung cancer risk in these data."
3.	Parkinson Disease (Parkinson's Disease) 01/01/1996 - "Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease." 02/24/1995 - "Moreover, 'poor debrisoquine metabolizer' phenotype is significantly increased in Parkinson's disease patients. " 08/01/1992 - "Debrisoquine (DBQ) metabolism was studied in 80 Parkinson's disease (PD) patients, 26 of whom had young onset Parkinson's disease (YOPD), and in 143 controls. " 08/01/1992 - "Debrisoquine hydroxylation in Parkinson's disease." 04/25/1992 - "Mutant debrisoquine hydroxylation genes in Parkinson's disease."
4.	Essential Hypertension 01/01/1999 - "The study was conducted on 10 patients of both sexes with mild to severe essential hypertension, aged 28 to 76 years, with normal hepatic and renal function and phenotyped as extensive metabolizers of debrisoquine (urine debrisoquine to 4-hydroxydebrisoquine ratios of 0.28 to 6.56). " 11/01/1983 - "Therefore, these components were evaluated in 11 normal subjects and 13 patients with mild essential hypertension before and after 4 weeks of sympathetic neuron blockade with the agent debrisoquine. " 01/01/1978 - "Clinical observation with debrisoquinsulphate (Tendor) in essential hypertension and glomerulonephritis." 05/01/1979 - "Debrisoquine lowered plasma norepinephrine by a similar degree (almost 50%) in these three groups; in contrast, blood pressure decreased only slightly in normal or borderline hypertensive subjects [-3.4 +/- 3.2% and -5.4 +/- 1.6% (SE), respectively] but fell significantly more (P less than 0.005) in patients with established essential hypertension (-20.7 +/- 3.9%). " 03/05/1990 - "A possible modulating influence of noradrenergic activity on serum lipoproteins was assessed under placebo conditions and following 4 weeks of sympathetic neurone blockade with debrisoquine in 9 normal subjects, 11 patients with mild essential hypertension, 9 normotensive, and 9 hypertensive hemodialysis patients. "
5.	Body Weight (Weight, Body) 01/01/1994 - "The trials were performed in 15 male healthy volunteers (age 21-25 years, body weight 62-94 kg, body height 172-187 cm) with known N-acetylation and debrisoquine type hydroxylation phenotype. " 09/01/1978 - "Body weight, blood volume, hematocrit and plasma sodium and potassium did not change significantly under debrisoquin while there was a slight but just significant increase in plasma volume. "

Related Drugs and Biologics

1.	Guanethidine
2.	Bethanidine (Batel)
3.	Cytochrome P-450 CYP2D6 (CYP2D6)
4.	Cytochrome P-450 Enzyme System (Cytochrome P450)
5.	Enzymes
6.	Antihypertensive Agents (Antihypertensives)
7.	Methyldopa (Aldomet)
8.	Mephenytoin (Mesantoin)
9.	Sparteine
10.	Dapsone

Related Therapies and Procedures

1.	Therapeutics
2.	Stem Cell Transplantation
3.	Transplantation
4.	Renal Dialysis (Hemodialysis)
5.	Drug Therapy (Chemotherapy)